| Diffuse Large B-Cell Lymphoma
Adcetris vs Columvi
Side-by-side clinical, coverage, and cost comparison for diffuse large b-cell lymphoma.Deep comparison between: Adcetris vs Columvi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsColumvi has a higher rate of injection site reactions vs Adcetris based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Columvi but not Adcetris, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Adcetris
Columvi
At A Glance
IV infusion
Every 2-3 weeks
CD30-directed antibody-drug conjugate
IV infusion
Every 3 weeks
CD20xCD3 bispecific T-cell engager
Indications
- Hodgkin Disease
- Angioimmunoblastic Lymphadenopathy
- Peripheral T-Cell Lymphoma
- Mycosis Fungoides
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
Dosing
Hodgkin Disease (previously untreated Stage III/IV, adults) 1.2 mg/kg (max 120 mg) IV in combination with chemotherapy every 2 weeks for a maximum of 12 doses.
Hodgkin Disease (previously untreated high risk, pediatric) 1.8 mg/kg (max 180 mg) IV in combination with chemotherapy every 3 weeks for a maximum of 5 doses.
Hodgkin Disease (post-auto-HSCT consolidation) 1.8 mg/kg (max 180 mg) IV every 3 weeks for a maximum of 16 cycles.
Hodgkin Disease (relapsed) 1.8 mg/kg (max 180 mg) IV every 3 weeks until disease progression or unacceptable toxicity.
Peripheral T-Cell Lymphoma, Angioimmunoblastic Lymphadenopathy (previously untreated) 1.8 mg/kg (max 180 mg) IV in combination with cyclophosphamide, doxorubicin, and prednisone every 3 weeks for 6 to 8 doses.
Peripheral T-Cell Lymphoma (relapsed systemic ALCL) 1.8 mg/kg (max 180 mg) IV every 3 weeks until disease progression or unacceptable toxicity.
Mycosis Fungoides (relapsed pcALCL or CD30-expressing) 1.8 mg/kg (max 180 mg) IV every 3 weeks for a maximum of 16 cycles.
Diffuse Large B-Cell Lymphoma (relapsed or refractory) 1.2 mg/kg (max 120 mg) IV in combination with lenalidomide and a rituximab product every 3 weeks until disease progression or unacceptable toxicity.
Diffuse Large B-Cell Lymphoma Pretreat with obinutuzumab 1,000 mg IV on Cycle 1 Day 1; then administer COLUMVI IV: 2.5 mg step-up dose on Cycle 1 Day 8, 10 mg step-up dose on Cycle 1 Day 15, then 30 mg on Day 1 of Cycles 2-12 (21-day cycles; maximum 12 cycles or until disease progression or unacceptable toxicity).
Contraindications
- Concomitant use with bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation)
—
Adverse Reactions
Most common (>=20%) Peripheral neuropathy, fatigue, nausea, diarrhea, musculoskeletal pain, pyrexia, rash, upper respiratory tract infection, constipation, alopecia
Serious Febrile neutropenia, pneumonia, hepatotoxicity, peripheral motor neuropathy, pulmonary toxicity, progressive multifocal leukoencephalopathy, tumor lysis syndrome, serious and opportunistic infections
Postmarketing Febrile neutropenia, acute pancreatitis, gastrointestinal complications, hepatotoxicity, progressive multifocal leukoencephalopathy, serious and opportunistic infections, hyperglycemia, noninfectious pulmonary toxicity including pneumonitis and ARDS, toxic epidermal necrolysis
Most common (>=20%) Cytokine release syndrome, musculoskeletal pain, rash, fatigue
Serious Cytokine release syndrome, COVID-19 infection, sepsis, tumor flare
Pharmacology
Brentuximab vedotin is a CD30-directed antibody-drug conjugate (ADC) consisting of a chimeric IgG1 anti-CD30 antibody linked to MMAE, a microtubule-disrupting agent; upon binding to CD30-expressing tumor cells the ADC is internalized and MMAE is released via proteolytic cleavage, disrupting the microtubule network within the cell and inducing cell cycle arrest and apoptosis.
Glofitamab-gxbm is a bispecific CD20-directed CD3 T-cell engager that binds CD20 on B cells and CD3 on T cells, causing T-cell activation and proliferation, cytokine secretion, and lysis of CD20-expressing B cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Adcetris
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Columvi
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Adcetris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Columvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Adcetris
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Columvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Adcetris Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Genentech Patient FoundationCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdcetrisView full Adcetris profile
ColumviView full Columvi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.